

K061238

510(k) Summary of Safety and Effectiveness Information

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

Submitter's Name: Lorraine H Piestrak
Dade Behring Inc.
P.O. Box 6101
Newark, DE 19714-6101

MAY 25 2006

Date of Preparation: May 2, 2005

Name of Product: Dimension Vista™ Carbon Dioxide (CO2) Flex® reagent cartridge
Dimension Vista™ Creatinine (CREA) Flex® reagent cartridge
Dimension Vista™ Lactate dehydrogenase (LDH) Flex® reagent cartridge

FDA Classification Name: Methods (Class II); Bicarbonate/Carbon Dioxide,
Creatinine, Lactate dehydrogenase test systems

Predicate Device:

The following table describes the predicate devices, device classification, regulation and product code associated with this pre-market notification:

New Product	Predicate	Predicate 510(k) #	Device class	Regulation	Product Code
Dimension Vista™ CO2 Flex® reagent cartridge	Dimension® ECO2 Flex® reagent cartridge	K010206	II	862.1160	KHS
Dimension Vista™ CREA Flex® reagent cartridge	Dimension® CREA Flex® reagent cartridge	K925668	II	862.1125	CGX
Dimension Vista™ LDH Flex® reagent cartridge	Dimension® LDH Flex® reagent cartridge	K860021	II	862.1440*	CFJ

* Not exempt from premarket notification per 862.9(c)(3)

Device Description:

Dade Behring Dimension Vista™ Flex® reagent cartridges are prepackaged in-vitro diagnostic test methods (assays) that are specifically designed to be used on the Dade Behring Dimension Vista™ Integrated system, a floor model, fully automated, microprocessor-controlled, integrated instrument system. The Dimension Vista™ system was previously cleared with seven associated test methods (K 051087).

This Special 510(k) is submitted for a packaging modification to *in-vitro* diagnostic devices that have been cleared under the 510(k) process for use on Dimension® clinical chemistry systems. The packaging change is to allow use on the Dimension Vista™ system.

The CO₂, CREA, and LDH reagents contained in the Dimension Vista™ Flex® reagent cartridges are the same as those contained in the Flex® reagent cartridges manufactured for the Dimension® clinical chemistry systems, another family of Dade Behring analyzers. The packaging modification, does not affect the intended use of the devices, nor does it alter the fundamental scientific technology of the devices.

Intended Use:

Dimension Vista™ Carbon Dioxide (CO₂) Flex® reagent cartridge:

The CO₂ method is an *in vitro* diagnostic test for the quantitative measurement of carbon dioxide in human serum and plasma on the Dimension Vista™ System.

Dimension Vista™ Creatinine (CREA) Flex® reagent cartridge:

The CREA method is an *in vitro* diagnostic test for the quantitative measurement of creatinine in human serum, plasma, and urine on the Dimension Vista™ System.

Dimension Vista™ Lactate dehydrogenase (LDH) Flex® reagent cartridge:

The LDH method is an *in vitro* diagnostic test for the quantitative measurement of lactate dehydrogenase in human serum and plasma on the Dimension Vista™ System.

Comparison to Predicate Device:

Both the Dimension Vista™ Flex® reagent cartridges and the predicate Dimension® Flex® reagent cartridges contain prepackaged reagents in flexible plastic, cartridges. A comparison of the important similarities and differences between the two Flex® cartridges is provided in the following table:

Feature	Dimension Vista™ Flex® reagent cartridge	Dimension® Analyzer Flex® reagent cartridge
Reagents	Prepackaged, 12-well plastic, Dade Behring Flex® reagent cartridges	Prepackaged, 6 & 8 well plastic, Dade Behring Flex® reagent cartridges
Intended Use	<i>in vitro</i> diagnostic use	<i>in vitro</i> diagnostic use
Indications for Use	Same as Dimension® analyzer	As described in 510(k)s for each previously cleared method.
Final concentration of sample/reagent ratio in test milieu	Same as Dimension® analyzer	As described in 510(k)s for each previously cleared method
Tablet Sizes	7/32"	7/32" & 9/32"
Total tests contained in each Flex® cartridge	Approximately three times more than contained in Dimension® Flex® reagent cartridges	As described in 510(k)s for each previously cleared method.
Calibration	30 to 90 days (determined for each method)	30 to 90 days As described in 510(k)s for each previously cleared method.

Comments on Substantial Equivalence:

The Dade Behring Dimension Vista™ Flex® reagent cartridges and the Dimension® Flex® reagent cartridges are designed similarly for the same purpose. Both contain prepackaged reagents for *in-vitro* diagnostic tests that are processed on microprocessor-controlled, integrated instrument systems to analyze a variety of analytes in human specimens.

The CO₂, CREA, and LDH reagents contained in the Dimension Vista™ Flex® reagent cartridges are the same as those contained in the Flex® reagent cartridges manufactured for the Dimension® clinical chemistry systems, another family of Dade Behring analyzers. The packaging modifications, do not affect the intended use of the devices, nor do they alter the fundamental scientific technology of the devices.

Comparative testing described in the protocol included in this submission demonstrates equivalent performance.

Conclusion:

The Flex® reagent cartridges, containing reagents for testing CO₂, CREA, and LDH on the Dimension® Vista™ Integrated system are substantially equivalent in design, principle, and performance to the Dimension® system Flex® reagent cartridges. They have the same intended use and indications for use. Comparative testing also demonstrates substantially equivalent performance.



Lorraine H Piestrak
Regulatory Affairs & Compliance Manager
May 2, 2006



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

MAY 25 2006

Food and Drug Administration
2098 Gaither Road
Rockville MD 20850

Ms. Lorraine H. Piestrak
Regulatory Affairs & Compliance Manager
Dade Behring, Inc.
PO Box 6101, M/S 514
Newark, DE 19714-6101

Re: k061238

Trade/Device Name: Dimension Vista™ Carbon Dioxide (CO2) Flex® reagent cartridge
Dimension Vista™ Creatinine (CREA) Flex® reagent cartridge
Dimension Vista™ Lactate dehydrogenase (LDH) Flex® reagent cartridge

Regulation Number: 21 CFR§862.1160

Regulation Name: Bicarbonate/carbon dioxide test system

Regulatory Class: Class II

Product Code: KHS, CGX, CFJ

Dated: May 2, 2006

Received: May 3, 2006

Dear Ms. Piestrak:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2 –

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Alberto Gutierrez", with a stylized flourish at the end.

Alberto Gutierrez, Ph.D.

Director

Division of Chemistry and Toxicology

Office of In Vitro Diagnostic Device

Evaluation and Safety

Center for Devices and

Radiological Health

Enclosure

Indications for Use

510(k) Number (if known): **K061238**

Device Name: Dimension Vista™ Carbon Dioxide (CO2) Flex® reagent cartridge

Indications For Use:

The Dimension Vista™ Carbon Dioxide (CO2) Flex® reagent cartridge is a device intended to measure carbon dioxide in serum and plasma. Measurements obtained by this device are used in the diagnosis and treatment of numerous potentially serious disorders associated with changes in body acid-base balance.

Prescription Use X
(Part 21 CFR 801 Subpart D)


AND/OR

Over-The-Counter Use _____
(21 CFR 801)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF
NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

Page 1 of 1


Division Sign-Off

Office of In Vitro Diagnostic Device
Evaluation and Safety

510(k) **K061238**

Indications for Use

510(k) Number (if known): K061238

Device Name: Dimension Vista™ Creatinine (CREA) Flex® reagent cartridge

Indications For Use:

The Dimension Vista™ Creatinine (CREA) Flex® reagent cartridge is a device intended to measure creatinine levels in serum, plasma and urine. Creatinine measurements are used in the diagnosis and treatment of renal diseases, in monitoring renal dialysis, and as a calculation basis for measuring other urine analytes.

Prescription Use X
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use
(21 CFR 801)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF
NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

Page 1 of 1


Division Sign-Off

Office of In Vitro Diagnostic Device
Evaluation and Safety

510(k) K061238

Indications for Use

510(k) Number (if known): K061238

Device Name: Dimension Vista™ Lactate dehydrogenase (LDH) Flex® reagent cartridge

Indications For Use:

The Dimension Vista™ Lactate dehydrogenase (LDH) Flex® reagent cartridge is a device intended to measure the activity of the enzyme lactate dehydrogenase in serum and plasma. Lactate dehydrogenase measurements are used in the diagnosis and treatment of liver diseases such as acute viral hepatitis, cirrhosis, and metastatic carcinoma of the liver, cardiac diseases such as myocardial infarction, and tumors of the lung or kidneys.

Prescription Use X
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use
(21 CFR 801)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF
NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

Page 1 of 1


Division Sign-Off

Office of In Vitro Diagnostic Device
Evaluation and Safety

K061238